Stockscreener 앱 받기
2.36
1.67%
-0.04
시간 외 거래:
2.32
-0.04
-1.69%
전일 마감가:
$2.40
열려 있는:
$2.44
하루 거래량:
1.47M
Relative Volume:
0.47
시가총액:
$440.47M
수익:
$7.25M
순이익/손실:
$-17.41M
주가수익비율:
-8.9836
EPS:
-0.2627
순현금흐름:
$-38.33M
1주 성능:
-7.81%
1개월 성능:
-15.71%
6개월 성능:
+49.37%
1년 성능:
+640.74%
1일 변동 폭
$2.32
$2.45
1주일 범위
$2.32
$2.625
52주 변동 폭
$0.272
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.36 | 447.94M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
442.96 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.34 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.41 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.16 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.49 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Roth Capital | Buy |
| 2025-11-17 | 개시 | Leerink Partners | Outperform |
| 2025-10-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-08 | 재개 | B. Riley Securities | Buy |
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media
Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Ovid Therapeutics joins June neuro investor conferences - Stock Titan
Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK
Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan
Press Release: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors - Moomoo
Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus
Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress By Investing.com - Investing.com South Africa
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com UK
OVID: Advancing novel therapies for seizures and psychosis with strong safety and market potential - TradingView
Ovid Therapeutics : May 2026 Corporate Presentation - marketscreener.com
Ovid Therapeutics Q1 net loss widens as R&D spending rises - TradingView
Ovid Therapeutics Inc. 1Q 2026: Revenue $0M, Net loss $17M, EPS $(0.12) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ovid Therapeutics (NASDAQ: OVID) widens Q1 loss but boosts cash to $165.6M - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) extends cash runway into 2029 - Stock Titan
TradingKey - TradingKey
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks - Yahoo Finance
Ovid Therapeutics (OVID) Eps Diluted (TTM) - Zacks Investment Research
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
MSN Money - MSN
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest - MarketBeat
OVID Earnings History & Surprises | EPS & Revenue Results | OVID THERAPEUTICS INC (NASDAQ:OVID) - ChartMill
Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan
SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow
[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ovid Therapeutics Inc 주식 (OVID) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.05%
0.26%
자본화:
|
볼륨(24시간):